

SIMONE MARSTILLER SECRETARY

November 1, 2021

## Statewide Medicaid Managed Care (SMMC) Policy Transmittal: 2021-31

Applicable to the 2018-2023 SMMC contract benefits for:

Managed Medical Assistance (MMA) and MMA Specialty

- Long-Term Care (LTC)
- Dental

## **Re: Monoclonal Antibody COVID-19 Infusion**

The Agency remains committed to ensuring enrollees diagnosed with the 2019 novel coronavirus (COVID-19) receive all the care needed to address their symptoms. As such, Florida Medicaid will continue to cover all medically necessary services to facilitate prevention and treatment of COVID-19, including **Monoclonal Antibody COVID-19 Infusion.** The purpose of this policy transmittal is to provide the billing details for Monoclonal Antibody COVID-19 Infusion.

Monoclonal Antibody COVID-19 Infusion received an <u>Emergency Use Authorization</u> (EUA) from the Food and Drug Administration. **Monoclonal Antibody COVID-19 Infusion must be provided in accordance with the EUA and <u>CMS guidelines</u>.** Florida Medicaid does not reimburse for home infusion.

The managed care plan must complete all necessary system programming for claims processing of the Monoclonal Antibody COVID-19 Infusion Healthcare Common Procedure Coding System (HCPCS) codes by November 30, 2021 and reprocess applicable claims paid during their effective dates within thirty (30) days of the pricing system update. The Florida Medicaid fee-for-service delivery system will reimburse for Monoclonal Antibody COVID-19 Infusions in accordance with the following rate information.

| HCPCS<br>Code | HCPCS Short<br>Descriptor      | Labeler<br>Name | Effective<br>Dates         | Medicaid<br>Fee for Service<br>Rate for Dates<br>of Service From<br>The Beginning<br>Effective Date<br>Through<br>05/05/2021 | Medicaid<br>Fee for Service<br>Rate for Dates<br>of Service<br>On or After<br>05/06/2021 |
|---------------|--------------------------------|-----------------|----------------------------|--|--|
| Q0239         | Bamlanivimab<br>700mg          | Eli Lilly       | 11/10/2020 –<br>4/16/2021  | *N/A   | Code inactive  |
| M0239         | Bamlanivimab<br>700mg Infusion | Eli Lilly       | 11/10/2020 –<br>04/16/2021 | ***\$185.76  | Code inactive  |



| HCPCS<br>Code | HCPCS Short<br>Descriptor                                  | Labeler<br>Name | Effective<br>Dates  | Medicaid<br>Fee for Service<br>Rate for Dates<br>of Service From<br>The Beginning<br>Effective Date<br>Through<br>05/05/2021 | Medicaid<br>Fee for Service<br>Rate for Dates<br>of Service<br>On or After<br>05/06/2021 |
|---------------|--|-----------------|---------------------|--|--|
| Q0240         | Casirivimab<br>300mg and<br>imdevimab 300mg<br>(600mg)     | Regeneron       | 07/30/2021 –<br>TBD | Code not active<br>during this time<br>period  | *N/A   |
| M0240         | Casirivimab and<br>imdevimab<br>Infusion Repeat            | Regeneron       | 07/30/2021 –<br>TBD | Code not active<br>during this time<br>period  | ***\$270.00  |
| Q0243         | Casirivimab<br>1200mg and<br>imdevimab<br>1200mg (2400mg)  | Regeneron       | 11/21/2020 –<br>TBD | *N/A   | *N/A   |
| M0243         | Casirivimab and<br>imdevimab<br>Infusion                   | Regeneron       | 11/21/2020 –<br>TBD | ***\$185.76  | ***\$270.00  |
| Q0244         | Casirivimab<br>600mg and<br>imdevimab 600mg<br>(1200mg)    | Regeneron       | 06/03/2021 –<br>TBD | Code not active<br>during this time<br>period  | *N/A   |
| Q0245         | Bamlanivimab<br>700mg and<br>etesevimab<br>1400mg (2100mg) | Eli Lilly       | 02/09/2021-<br>TBD  | *N/A   | *N/A   |
| M0245         | Bamlanivimab and<br>etesevimab<br>Infusion                 | Eli Lilly       | 02/09/2021-<br>TBD  | ***\$185.76  | ***\$270.00  |
| Q0247         | Sotrovimab 500mg   | GSK             | 05/26/2021 –<br>TBD | Code not active<br>during this time<br>period  | **Priced per<br>Rule 59G-4.251,<br>F.A.C.  |
| M0247         | Sotrovimab<br>Infusion                                     | GSK             | 05/26/2021 –<br>TBD | Code not active<br>during this time<br>period  | ***\$270.00  |
| Q0249         | Tocilizumab 1mg<br>for COVID-19                            | Genentech       | 06/24/2021 -<br>TBA | Code not active<br>during this time<br>period  | **Priced per<br>Rule 59G-4.251,<br>F.A.C.  |
| M0249         | Admin Tocilizumab<br>1mg COVID-19 1 <sup>st</sup><br>Dose  | Genentech       | 06/24/2021 -<br>TBA | Code not active<br>during this time<br>period  | ***\$270.00  |

Statewide Medicaid Managed Care (SMMC) Policy Transmittal 2021-31 Re: Monoclonal Antibody COVID-19 Infusion November 1, 2021 Page 3 of 3

| HCPCS<br>Code | HCPCS Short<br>Descriptor                                 | Labeler<br>Name | Effective<br>Dates  | Medicaid<br>Fee for Service<br>Rate for Dates<br>of Service From<br>The Beginning<br>Effective Date<br>Through<br>05/05/2021 | Medicaid<br>Fee for Service<br>Rate for Dates<br>of Service<br>On or After<br>05/06/2021 |
|---------------|---|-----------------|---------------------|--|--|
| M0250         | Admin Tocilizumab<br>1mg COVID-19 2 <sup>nd</sup><br>Dose | Genentech       | 06/24/2021 -<br>TBA | Code not active<br>during this time<br>period  | ***\$270.00  |

\*Rates with an N/A are supplied Federally at no cost.

\*\*Priced in accordance with Rule 59G-4.251, Florida Administrative Code (F.A.C.). \*\*\*Administration services are reimbursed at 80% of the maximum fee when performed by an advanced practice registered nurse (APRN) or physician's assistant (PA).

The Fee Schedule Lookup Tool is available on the Medicaid Fiscal Agent website http://portal.flmmis.com/FLPublic/Provider\_ProviderServices/Provider\_ProviderSupport/Provider \_ProviderSupport\_FeeSchedules/tabld/51/Default.aspx, for use by providers, health plans, and other stakeholders. The Fee Schedule Look-up Tool allows the user to enter a HCPCS/CPT code to determine the reimbursement rate for a specific date of service.

If you have questions, contact your Agency contract manager at (850) 412-4004.

Sincerely,

Tom Wallace Deputy Secretary for Medicaid

TW/sar